Living with Ankylosing Spondylitis EU and US 2019 report

Living with ankylosing spondylitis (AS) is a quantitative study conducted online amongst give the total number 365 patients diagnosed with AS in the 5 EU; up to 100 of these will be classified as likely nr-AxSpA in the 5 EU markets (France, Germany, Italy, Spain, UK). In the US, the study is conducted with 105 AS patients and 30 nr-AxSpA patients. The report consists of quantitative 30 minute quantitative online interviews and qualitative tele-depth interviews, and will be published in the 1st quarter 2019.

The report is intended to help pharmaceutical companies developing products in AS and nr-AxSpA to gain a deeper understanding of how patients come to be diagnosed with it and how it impacts their day-to-day lives physically, emotionally and socially. It also explores patient attitudes and perceptions towards treatment, the healthcare professionals managing their condition, as well as identifying the types of support and education patients need at key stages of their journey.

AS is a form of progressive arthritis due to chronic inflammation of the joints in the spine. Most patients typically first experience AS symptoms in their teen years up to the age of 30 years old, meaning symptoms impact AS patients for a long period of time into their adult years.

Head of Living With, Mariel Metcalfe commented, “People living with AS and nr-AxSpa experience high levels of unmet need, and diagnosis of the condition can be lengthy for some. The report focuses on not only the experiences of these people, but also what more can be done to help support them medically, emotionally and socially.”

To discover more, download our new interactive infographic to unlock key insights from various Living With reports to reveal patient behaviours, attitudes and unmet needs at different stages of their chronic disease journey. Download the infographic »

Find out more about our Living With reports »